Could Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Change Direction After More Shorts?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.17 in 2019 Q2. Its down 0.32, from 1.49 in 2019Q1. It dived, as 36 investors sold Jazz Pharmaceuticals plc shares while 105 reduced holdings. 52 funds opened positions while 113 raised stakes. 50.63 million shares or 4.18% more from 48.59 million shares in 2019Q1 were reported.
Royal National Bank Of Canada invested in 0.01% or 174,730 shares. State Of Alaska Department Of Revenue stated it has 6,835 shares or 0.02% of all its holdings. Ftb Advisors Inc reported 132 shares stake. Assetmark Incorporated, California-based fund reported 24 shares. Japan-based Mitsubishi Ufj Holdg has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Sit Investment reported 5,700 shares. Amalgamated Fincl Bank holds 12,119 shares or 0.04% of its portfolio. Confluence Management Ltd Liability Company holds 0.01% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 4,243 shares. 179 were reported by Service Corporation. Moreover, State Common Retirement Fund has 0.02% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 127,762 shares. Paloma Prns Management stated it has 0.04% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Citigroup has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Verition Fund Mngmt Ltd has invested 0.05% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). British Columbia Inv Management, a British Columbia – Canada-based fund reported 54,413 shares. Peoples Financial Service reported 36 shares.

The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24M shares in October as published by FINRA. Its up 10.97% from 2.02 million shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.

The stock increased 0.60% or $0.71 during the last trading session, reaching $118.67. About 369,908 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since October 12, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $6.72 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 10.76 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 4 analysts covering Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Jazz Pharmaceuticals plc – Ordinary Shares has $20800 highest and $14200 lowest target. $165.50’s average target is 39.46% above currents $118.67 stock price. Jazz Pharmaceuticals plc – Ordinary Shares had 5 analyst reports since May 8, 2019 according to SRatingsIntel. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Neutral” rating by Mizuho on Wednesday, May 8. BMO Capital Markets maintained it with “Outperform” rating and $20800 target in Wednesday, May 8 report. The firm earned “Neutral” rating on Wednesday, August 21 by Piper Jaffray.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: which released: “Great Places to Retire Near the Beach 2019 – Nasdaq” on September 19, 2019, also with their article: “The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda’s Ulcerative Colitis Drug Found Superior To AbbVie’s, Decision Day For J&J – Yahoo Finance” published on September 26, 2019, published: “Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update – PRNewswire” on September 18, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: and their article: “Here’s Why I Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Is An Interesting Stock – Yahoo Finance” published on September 07, 2019 as well as‘s news article titled: “Jazz Pharmaceuticals signs multimillion-dollar deal for experimental cancer therapy – Philadelphia Business Journal” with publication date: July 10, 2019.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.